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Abstract
The prognostic value of visceral pleural infiltration in lung metastasis was analysed. Fifty-two patients (32 males and 20 females) were
operated on for lung metastases. The locations of the primary tumours were as follows: 19 colon, 10 kidneys, 8 melanomas, 3 breast, 3
bladder, 2 uterus, 2 osteosarcomas, 1 testis, and 1 parotid, 1 haemangiopericytoma, 1 thyroid gland and 1 larynx. Explorative thoracotomies
and incomplete resections were excluded from the study. Visceral pleural infiltration was present in 20 of the 52 cases. There was a
significant correlation between the occurrence of pleural infiltration and multiple lesions (Ps0.019). The overall five-year survival rate
was 33.6%. In a subgroup of 38 patients with N0 and single metastases, the five-year survival rate was 73% and 12% in the cases without
and with visceral pleural infiltration, respectively (Ps0.003). Multivariate analysis of pleural infiltration, lymph node metastasis, multiple
lesions and DFI revealed that only pleural infiltration (Ps0.003) had a significant impact on survival. In one-third of the pulmonary
metastases, visceral pleural infiltration appeared. There was a significant correlation between the occurrence of visceral pleural infiltration
and multiple lesions. Visceral pleural infiltration in lung metastasis is a negative prognostic factor, and in these cases, survival was
significantly reduced.
 2007 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
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1. Introduction
Pulmonary metastasectomy is a standard procedure in
selected cases to remove secondary malignant lesions from
the lung parenchyma, and many studies have confirmed
the indications, the technical principles, and the results of
this surgical procedure w1–5x. Recently, emerging experi-
ences, survival rates and prognostic factors after metasta-
sectomies were evaluated. From an analysis of 5206 lung
metastasectomies from 18 thoracic surgery departments in
Europe, the United States and Canada, The International
Registry of Lung Metastases has confirmed that the resect-
ability, disease-free interval (DFI), and the number of
metastases can predict the rate of survival after metasta-
sectomy w1x. Furthermore, in cases of metastases from
colorectal carcinoma, the unilateral or bilateral locations
of metastases, the Dukes’ status of the primary tumour,
the carcinoembryonic antigen (CEA) level, and hilar or
mediastinal lymph node involvement can be used as post-
operative prognostic factors w2–5x.
In primary lung cancer cases, the prognosis can be pre-
dicted from tumour (T), lymph node involvement (N), and
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metastasis (M) (TNM) data w6x, but in pulmonary metastasis
cases only the N and the M (multiple lesions) status were
relevant prognostic factors.
In primary lung cancer staging, pleural infiltration
upgrades the T status from T1 to T2, and leads to a poorer
survival prognosis. The literature contains very little infor-
mation on the influence of the loco-pathological status of
the metastatic tumour upon survival, as has been detailed
in primary lung cancer cases. In this retrospective study,
we analysed the prognostic value of visceral pleural infil-
tration in lung metastasis and survival.
2. Material and methods
Fifty-two patients with pulmonary metastases underwent
complete pulmonary metastasectomies in our thoracic
department. There were 32 males and 20 females, and the
mean age was 60.5 (20–86) years. Cases with explorative
thoracotmies and incomplete resections were excluded
from this study.
The four synchronous lesions were defined as those iden-
tified within three months of the primary tumour resection.
The 48 metachronous lesions were identified as metastatic
lesions that presented more than three months after the
resection of the original malignant tumour w7x.
The criteria for pulmonary metastasectomy were as fol-
lows: (1) the patient had to be able to tolerate the
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Table 1
Types of primary tumours and pulmonary resections
No. of cases Percentage
Patients 52 100
Primary tumour
Colorectal 19 37
Renal 10 19
Melanoma 8 15
Breast 3 6
Bladder 3 6
Uterine 2 4
Osteosarcoma 2 4
Testicular 1 2
Parotid 1 2
Haemangiopericytoma 1 2
Thyroid gland 1 2
Laryngeal 1 2
Resection
Total number of resections 52 100
Wedge resection 28 54
Lobectomy 22 42
Pneumonectomy 2 4
Unilateral resection 47 90
Bilateral resection 5 10
Table 3
Correlation between visceral pleural infiltration and lymph node involvement
and adjuvant therapy and disease-free interval and number of metastases
PL0 PLq P-value
N0 29 15
Nq 3 5 0.235
DFI-36 months 14 7
DFI)36 months 18 13 0.575
Single metastasis 30 13
Multiple metastases 2 7 0.019
No adjuvant therapy 19 9
Adjuvant therapy 13 11 0.395
N0: lymph nodes without metastasis; Nq: Lymph nodes with metastasis;
PL0: non-pleural infiltration; PLq: pleural infiltration; DFI: disease-free
interval.
Table 2
Pathology of metastases in 52 patients
No. of cases Percentage
Non-pleural infiltration (PL0) 32y52 62
Pleural infiltration (PLq) 20y52 38
Colorectal 9y19
Renal 4y10
Melanoma 2y8
Breast 1y3
Bladder 1y3
Testicular 1y1
Haemangiopericytoma 1y1
Laryngeal 1y1
PL0: non-pleural infiltration. PLq: pleural infiltration.
metastasectomy; (2) the primary tumour was controlled;
(3) there were no other extrapulmonary metastasis, or, if
this was present, it could be controlled by surgery or some
other treatment modality; (4) the pulmonary metastasis
was considered to be completely resectable; (5) no other
effective treatment mode was available except resection
w8x.
The preoperative evaluation in every cases included a
chest X-ray, chest computed tomography (CT), bone scin-
tigraphy, brain CT, bronchoscopy and spirometry for lung
capacity. The site of the primary tumour was evaluated,
e.g. via abdominal CT, mammography and colonoscopy.
The surgical approach was a posterolateral thoracotomy
or sequential posterolateral thoracotomy with a 4–6-week
interval. One VATS metastasectomy was performed on an
86-year-old patient. Parenchyma-sparing resections were
carried out with complete mediastinal block dissections.
Twenty-four of the 52 patients received adjuvant therapy
after the metastasectomies (6 irradiations and 18
chemotherapies).
All histological examinations were made by the same
pathologist. Visceral pleural infiltration was diagnosed if
the intraparenchymal metastasis invaded the visceral
pleura.
The types of the primary tumours and the resections are
shown in Table 1.
For statistical evaluation, the data were analysed with
SPSS (Statistical Package for Social Science, SPSS Inc,
Chicago, IL) software for Windows. With the Kaplan–Meier
method, the survival was calculated from the time of the
first metastasectomy to the last follow-up or the time of
death. Significance was calculated with the log-rank test.
3. Results
There was no 30-day mortality. The mean DFI was 56.1
(1–377) months.
Twenty of the 52 cases involved visceral pleural infiltra-
tion (PLq) as intraparenchymal metastasis, and there were
32 non-pleural infiltration (PL0) cases. The pathology of
the mestastases is detailed in Table 2.
There was no significant correlation between pleural
infiltration and lymph node metastasis (0.235), or between
pleural infiltration and DFI () or - 36 months) (Ps0.575),
but the correlation between pleural infiltration and multi-
ple metastases was significant (Ps0.019).
There was no significant correlation between pleural
infiltration and the cases with adjuvant therapy (Ps0.395)
(Table 3).
The overall five-year survival rate was 33.6%. Survival
data are presented in Table 4.
To analyse the impact of pleural infiltration on the surviv-
al, a very homogeneous subgroup was made, which may be
pathologically similar to stage I lung cancer (N0 status,
complete resection, and single metastasis). There were 38
patients in this subgroup; the five-year survival was 73%
and 12% (Ps0.003) in the 27 PL0 and 11 PLqcases, respec-
tively. The survival distribution in this subgroup can be
seen in Fig. 1.
The univariate analyses revealed that pleural infiltration
(Ps0.001), lymph node metastasis (Ps0.007), and multi-
ple metastases (Ps0.009) had a significant impact on
survival; the influence was not significant for DFI (Ps0.346)
and adjuvant therapy (Ps0.791). Survival data are pre-
sented in Table 4. Multivariate analysis of pleural infiltra-
tion, lymph node metastasis, DFI, adjuvant therapy and
multiple lesions indicated that only pleural infiltration
(Ps0.003) was a significant prognostic factor for survival,
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Table 4
Survival data (univariate analysis)
Patients (No.) Five-year survival (%) P-value
Overall survival 52 33.6
Pleural infiltration (PLq) 20 6
Non-pleural infiltration (PL0) 32 59 0.001
Lymph node metastasis (Nq) 8 0
Lymph node-negative (N0) 44 41 0.007
Multiple metastases 9 0
Single metastasis 43 45 0.009
DFI)36 months 31 38
DFI-36 months 21 25 0.346
Adjuvant therapy 24 30
No adjuvant therapy 28 38 0.791
N0: lymph nodes without metastasis; Nq: lymph nodes with metastasis; PL0: non-pleural infiltration; PLq: pleural infiltration; DFI: disease-free interval.
Table 5
Multivariate analysis (Cox Regression)
Wald sig. Odds ratio 95.0% CI
Lower Upper
Pleural infiltration 0.003 4.262 1.617 11.233
Lymph node metastasis 0.055 2.830 0.977 8.197
Multiple metastases 0.665 1.263 0.184 1.028
DFI 0.058 0.435 0.439 3.633
Adjuvant therapy 0.661 0.830 0.362 1.907
DFI: disease-free interval; Sig.: significance; CI: Confidence interval.
Fig. 1. Survival in the N0-single metastasis subgroup.
and lymph node metastasis (Ps0.055), DFI (Ps0.058),
adjuvant therapy (Ps0.661) and multiple metastases
(Ps0.665) had no significant impact on survival. Data in
multivariate analysis are presented in Table 5.
4. Discussion
Pulmonary metastasectomy should be a parenchyma-spar-
ing resection of secondary malignant lesions, and this
principle is supported by the data from three multicentral
studies w1, 9, 10x. In our practice, the rate of sublobar
resection was 54%, lobectomy was 42% and pneumonectomy
was 4%, which are very similar to the corresponding data
from the above-mentioned studies: 75%-62%-73%, 21%-35%-
24%, 2.5%-1.8%-1.3%, respectively. Our approach is a pos-
terolateral thoracotomy; in bilateral cases we prefer
sequential, posterolateral thoracotomies, as recommended
by Saito et al. w9x.
The stage and prognosis of a primary tumour can be given
in terms of the TNM system, and this is well detailed in
lung cancer cases w6x. However, in cases with resectable
pulmonary metastases, the pathological structure of the
secondary pulmonary tumour has not been widely detailed.
Few studies have been published on visceral pleural infil-
tration in pulmonary metastasis cases. In the study by
Shiono et al. w11x, the rate of pleural infiltration by the
pulmonary metastases from colorectal carcinoma was 7%.
There was no local recurrence among the pleural infiltra-
tion cases, but the survival was not analysed in that study.
In our series, the rate of visceral pleural infiltration was
38%, and 47% (9y19) among colorectal metastases. Mori et
al., presented a case-report with two osteosarcoma metas-
tases with parietal pleural migration w12x.
Our study did not reveal a significant correlation between
visceral pleural infiltration of the metastasis and lymph
node metastasis, or between visceral pleural infiltration
and DFI, but a significant correlation was demonstrated
between visceral pleural infiltration and multiple metas-
tases (Ps0.019). By univariate analysis, multiple metasta-
ses had a significant impact on survival compared to solitary
metastasis (0% vs. 45%) (Ps0.009), but the multivariate
analysis did not indicate a significant impact of multiple
lesions on survival. In the breast cancer metastasis study
by Friedel et al., on behalf of the International Registry of
Lung Metastases, no significant difference in the five-year
survival rate was found between solitary metastases (44%)
and multiple metastases (25%) w10x, whereas Hofmann
et al., found a significant difference in five-year survival
between single (54.7%) and multiple metastases (29.8%) in
renal cell carcinoma w13x. Okumura et al., reported a
significant difference in five-year survival between the
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solitary (52.5%) and multiple (25.5%) metastases in colo-
rectal cases w2x, but Sakamoto et al., did not confirm this
(51% vs. 47%) w14x.
The incidence of lymph node metastasis in our series was
15.4%. It was 15% in the investigation of colorectal cases
by Okumura et al. w2x, and 5% in the Pastorino and the
International Registry of Lung Metastases study w1x. In our
work, the five-year survival rate in lymph node metastasis
cases (Nq) was 0%, and in cases without lymph node
metastasis (N0) was 41% (Ps0.007). Only the univariate
analysis indicated that lymph node involvement had a
significant impact on the survival, but by multivariate
analysis, the lymph node metastasis was not a significant
prognostic factor for survival (Ps0.055). This finding is
similar to that in the study by Ercan et al., who recom-
mended complete mediastinal lymph node dissection,
which was a standard procedure in our practice too w15x.
The five-year overall survival rate in our patients was
33.6%, which is similar to the 32.4% reported in colorectal
w4x and 38% in breast cancer w10x metastasectomies, 30% in
colon tumours with hepatic and pulmonary metastasectases
w7x.
In primary lung cancer, visceral pleural infiltration is
associated with an upgrade of the tumour from T1 to T2,
and the survival is reduced from 67% in pathologic stage
IyA to 57% in pathologic stage IyB w6x. Our study with
completete metastasectomies has revealed the same ten-
dency. The five-year survival rate in a homogeneous sub-
group of patients with N0 and single metastasis,
pathologically very similar to stage I lung cancer cases, was
73% and 12% in non-pleural infiltration and in visceral
pleural infiltration cases, respectively (Ps0.003).
We can conclude that in one-third of the pulmonary
metastases, visceral pleural infiltration could be found.
The visceral pleural infiltration from pulmonary metastasis,
significantly reduces the survival rate in patients who have
undergone metastasectomy. Multivariate analysis demon-
strates that only the visceral pleural infiltration has signif-
icant effects on the survival rate. The presence of pleural
infiltration should be considered in any assessment of the
prognosis after pulmonary metastasectomy.
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Conference discussion
Dr P. Van Schil (Antwerp, Belgium): Was visceral pleural invasion a
significant independent prognostic factor in the multivariate analysis?
Dr Furak: Yes.
Dr Van Schil: And did you look at the local recurrences?
Dr Furak: We had 8.5% of local recurrence.
Dr Van Schil: In those patients with visceral pleural invasion?
Dr Furak: Yes, I mean almost half of them local and lymph node recurrence.
Dr Van Schil: So the question remains whether those patients are dying of
local recurrence or other distant metastases.
Dr Furak: Systemic, because there was a very close correlation between
multiple lesions and pleural infiltration.
Dr A. End (Vienna, Austria): Do you perform lymph node dissection in any
case?
Dr Furak: It’s a routine procedure in our surgery.
Dr End: Do you also perform mediastinoscopy?
Dr Furak: No. During the surgery we performed block dissection.
Dr End: In case of pleural infiltration, do you consider a more aggressive
adjuvant therapy?
Dr Furak: That’s it. I think this is the most important message of this
statement.
Dr A. Tcherveniakov (Sofia, Bulgaria): Yesterday we had a discussion
about the locations of the metastatic lung lesions. Do you have any specific
data about the localizations of the metastatic tumors? In my opinion the
upper lobes are more frequent site of recurrence than the lower lobes.
Dr Furak: The tendency was that one! The metastasis was a little bit more
frequent in the upper part of the lung, but I cannot tell you the correct
data currently.
